Insights Into the Biological Role of NEDD4L E3 Ubiquitin Ligase in Human Cancers

Shangdan Xie, Lu Xia, Yizuo Song, Hejing Liu, Zhi-wei Wang* and Xueqiong Zhu*

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Neural precursor cell expressed developmentally downregulated 4-like (NEDD4L) is an E3 ubiquitin ligase that has been reported to participate in multiple cellular procedures by regulating of substrate ubiquitination and subsequent protein degradation. A great amount of evidence has demonstrated that NEDD4L mainly functions as a tumor suppressor in most cancer types, while it also acts as an oncogene in a few cancers. In this review, we summarize the potential role of NEDD4L in carcinogenesis and the related underlying molecular mechanism to improve our understanding of its functions in the tumorigenesis of human malignancies. Developing clinical drugs targeting NEDD4L could be a potential therapeutic strategy for cancer therapy in the future.

Keywords: NEDD4L, ubiquitination, cancer, treatment, degradation

INTRODUCTION

Ubiquitination is a cellular biological process that specifically modifies posttranslational proteins and results in substrate degradation, stabilization or relocation (1). Several successive enzyme reactions constitute a cascade of ubiquitination. Ubiquitin was originally linked to E1 ubiquitin activating enzymes for its activation in an ATP-dependent manner and then instantaneously shifted to E2 ubiquitin conjugating enzymes. Afterward, the transfer of ubiquitin from E2 to the substrate is mediated by E3 ubiquitin protein ligases (E3s) (2, 3). Abnormalities of ubiquitination have been confirmed to be related to tumor occurrence and development (4). It is known that E3s determine the substrate specificity of the system to a large extent (5); therefore, the disorders of E3s might lead to the initiation of human cancer.

To date, there have been more than 600 E3s in the human genome, which are mainly sorted into three categories: really interesting new gene (RING) finger family E3s, the RING-between-RING (RBR) family E3s, and homologous to the E6-AP C-terminus (HECT) family E3s (6). HECT family E3s have an active site for cysteine, where cysteine binds to ubiquitin for an intervening thioester prior to its substrate (7). Specific recognition of substrates is based on the nonconservative N-terminus of HECT family E3s (8). As the most familiar and studied group of HECT family E3s, the neural precursor cell expressed developmentally downregulated 4 (NEDD4) subfamily has nine members, including NEDD4 (known as NEDD4-1), NEDD4-like (NEDD4L, also named NEDD4-2), ITCH, Smurf1, Smurf2, WWPI1, WWP2, NEDL1 (also named HECW1) and NEDL2.
(also named HECW2), and is characterized by a WW domain and a C2 domain (9, 10). NEDD4-like, is a member of the NEDD4 subfamily and is reported to regulate various ion channels and virus budding (11). NEDD4L plays a potential role in the growth of the central nervous system, the regulation of hypertension and the development of cancer and so on (12). In recent years, compelling evidence has shown that NEDD4L accelerates or weakens the progression of various types of cancers by targeting different substrates (13, 14). As a result, this review presents the structure of NEDD4L and aims to summarize the function of NEDD4L in diverse cancer types.

**STRUCTURE AND FUNCTION OF NEDD4L**

In the NEDD4 ubiquitin ligase family, NEDD4L is the most analogous homolog of NEDD4, the archetypal member of the family (15). NEDD4L is widely distributed and highly conserved in vertebrates (11). Human NEDD4L is located on chromosome 18q21.31 and has 41 exons. NEDD4L exists as two protein bands in various tissues, including human tissue, one of which changes marginally due to tissue specificity, and the other one, a stably expressed protein, containing an N-terminal C2 domain, 4 WW domains and a C-terminal HECT domain (Figure 1) (11). The chief function of the C2 domain consists of Ca\(^{2+}\) binding, membrane targeting and protein-protein interactions (16). The WW domains play a pivotal role in discriminating and provoking the specific substrates of NEDD4L (17). The HECT domain contains the catalytic cysteine 42 and participates in catalyzing polyubiquitin chain packaging, a two-step mechanism implicated in two E2 ubiquitin binding sites (18). The C2 domain and the HECT domain restrain each other to control their own activity in normal circumstances (19). This state of equilibrium is broken when intracellular Ca\(^{2+}\) binds to the C2 domain, thus stimulating the ubiquitin ligase activity of NEDD4L and then recruiting it to the plasma membrane (20). Expectedly assembling substrate-linked ubiquitin chains, including Lys-63, Lys-48, Lys-27, Lys-11 and Lys-6 linkages, NEDD4L can result in substrate degradation by lysosomes or the proteasome, and/or change the cell signaling pathway (18, 21, 22).

The original and most familiar function of NEDD4L is to regulate the epithelial Na\(^{+}\) channel (ENaC), which is closely related to the fluctuation of blood pressure (23). In addition, NEDD4L also participates in DNA repair, antiviral immunity and tumor development (24–26). To date, multiple reports have shown that the expression of NEDD4L in cancers is abnormal, and various proteins have been validated to bind with NEDD4L or be ubiquitinated by NEDD4L, thus modulating the cancer development (27). For instance, DNA damage-binding protein 2 (DDB2) suppresses the expression of NEDD4L and then affects the transforming growth factor-\(\beta\) (TGF-\(\beta\)) signaling in ovarian cancer (28). This review focuses on the potential role and related molecular mechanisms of NEDD4L in carcinogenesis and tumor progression.

**THE INVOLVEMENT OF NEDD4L IN DIFFERENT SIGNALING PATHWAYS**

NEDD4L is implicated in the regulation of various signaling pathways. For example, NEDD4L induced the ubiquitination of Unc51-like kinase 1 (ULK1), an autophagy initiation related protein, to control autophagy (29, 30). Endoplasmic reticulum stress increases the level of NEDD4L to trigger autophagy (31). 8-Oxoguanine DNA glycosylase (OGG1) is the central cellular enzyme applied in the excision of 8-oxoguanine DNA base lesions in DNA via the base excision repair pathway, and NEDD4L is involved in OGG1 ubiquitylation in response to DNA damage (24). In addition, NEDD4L catalyzed Dishevelled 2 (Dvl2) polyubiquitination, and Dvl2 was considered as a major mediator of both Wnt/\(\beta\)-catenin and Wnt/planar cell polarity pathways (21), suggesting that NEDD4L inhibited Wnt signaling. In addition, NEDD4L mediated the ubiquitination of PIK3CA and then weakened PI3K-AKT signaling (32). It was also reported that NEDD4L might enhance MAPK/ERK signaling but few studies have focused on concrete mechanisms (13). The specific recognition of the TGF-\(\beta\)-triggered phosphoThr-ProTyr motif in the junction region by the WW domain of NEDD4L contributed to Smad2/3 polyubiquitination and degradation, thus inhibiting TGF-\(\beta\) signaling (33).

---

**FIGURE 1** The structure of NEDD4L is illustrated.
THE FUNCTION OF NEDD4L IN CANCER

Gastric Cancer
Gastric cancer ranks the fifth among the most common cancers and is the third-leading cause of cancer death (34). To date, it has been reported that the expression of NEDD4L is positively related to the outcomes of gastric cancer patients (35). Patients with negative NEDD4L expression tended to have lymphatic infiltration, metastasis and vascular invasion in sharp contrast to those with positive NEDD4L expression (35). In addition, a high level of NEDD4L generally corresponded to a low level of HIF-1α in gastric cancer tissues and led to a favorable prognosis (36). Collectively, NEDD4L might affect the metastasis of gastric cancer and together with HIF-1α, could predict the prognosis of patients. However, further experiments at the cellular and animal levels are needed to test the function of NEDD4L in gastric cancer development.

Liver Cancer
Liver cancer, the second most lethal cancer worldwide, emerges in approximately 900,000 people and causes about 830,000 patient deaths every year (37). In hepatocellular carcinoma (HCC), the Wnt/β-catenin signaling pathway is frequently abnormally regulated (38). A study showed that the expression of NEDD4L was elevated when Wnt/β-catenin was activated in HCC (39). However, another study revealed that the decreased expression of NEDD4L could enhance the proliferation ability of HCC cells (13). In an in vivo experiment, overexpression of NEDD4L attenuated the growth of xenograft tumors in nude mice (13). In addition, both of in vivo and in vitro experiments suggested that NEDD4L might advance the MAPK/ERK signaling pathway to weaken the proliferation of HCC cells via the induction of apoptosis (13). In patients, it was found that the expression of NEDD4L in HCC tissues was lower than that in paracancerous tissues and the patients with high NEDD4L expression had better outcomes than those with low expression of NEDD4L (13). Consequently, NEDD4L might act as a tumor-suppressor gene to repress the malignant biological behavior of HCC, while the relationship between NEDD4L and the Wnt/β-catenin signaling pathway needs further investigation to prove.

Colorectal Cancer
Colorectal cancer (CRC) is the third most frequent cancer and the second most deadly cancer globally (37). By inhibiting the destruction of the LGR5 receptor, the absence of NEDD4L could facilitate the signal transduction of Wnt/β-catenin and the number of intestinal stem cells, thus promoting the susceptibility and progression of colorectal tumors (40). Moreover, the expression of NEDD4L was all reduced in various stages of colorectal cancer specimens, in contrast to that in adjacent normal mucosal tissues. NEDD4L significantly suppressed the Wnt/β-catenin signaling pathway in CRC cells (41). NEDD4L can degrade serine/threonine kinase 35 (STK35) by ubiquitination and then inhibit glycolysis, increasing the apoptosis of CRC cells by suppressing the Akt signaling pathway and modulating the chemoresistance of CRC cells (42).

In addition, a study revealed that the expression of NEDD4L in rectal cancer patients was upregulated after radiotherapy, suggesting that NEDD4L might be helpful for the treatment of rectal cancer patients (43). Taken together, NEDD4L possibly weakens the development of CRC and more in vivo experiments are required to validate the function of NEDD4L.

Pancreatic Cancer
Pancreatic cancer is a malignant cancer with a poor prognosis and takes approximately 466,000 lives away every year (37). Mounting studies have discovered that NEDD4L plays a pivotal role in the development of pancreatic cancer. MicroRNA-23A (miR-23A) inhibits the expression of NEDD4L to collaborate with miR-21 and miR-27A, thus promoting the progression of pancreatic cancer (44, 45). NEDD4L was demonstrated to be linked to iron metabolism in pancreatic cancer. N-myc downstream regulated gene-1 (NDRG1), an iron-regulated metastasis suppressor, upregulated the expression of NEDD4L in PANC1 pancreatic cancer cells (46). NEDD4L mediates the degradation of the iron-binding transport protein lactotransferrin (LTF) by ubiquitination to hinder the malignant biological behavior of pancreatic cancer (47). Besides, NEDD4L impeded autophagy and cancer cell proliferation by being involved in the degradation of ULK1, and weakening the expression of the glutamine transporter ASC1T2 by the ubiquitination pathway in pancreatic cancer (30). Hence, NEDD4L acts as a tumor-suppressor gene in pancreatic cancer.

Gallbladder Cancer
Although gallbladder cancer is an uncommon cancer, delayed diagnosis and poor prognosis are distinctive features (48). A study demonstrated that the expression of NEDD4L in the cytoplasm of invasive cancer cells is much higher than that in normal or dysplastic epithelial cells (14). Furthermore, NEDD4L enhanced the invasion ability of gallbladder carcinoma cells by increasing metalloproteinase-1 (MMP-1) and MMP-13 expression (14). Interestingly, downregulation of NEDD4L did not affect cell growth in gallbladder cancer (14). Unlike with most cancer types, NEDD4L might exert a tumor-promoting effect on gallbladder cancer.

Lung Cancer
Lung cancer is the main cause of cancer death and seriously threatens the lives of people worldwide (49). It was reported that NEDD4L is considered as one of the central drivers in lung adenocarcinoma (LUAD) and might affect the prognosis of the patients (50). Downregulation of NEDD4L was found in nonsmall cell lung cancer (NSCLC) samples in contrast to those of normal tissues. In NSCLC patients, NEDD4L rs11660748 A>G and rs73440898 A>G had adjusted hazard ratios (HRs) of 1.31 and 1.27, respectively, for overall survival, which means that the mutations at these two sites might impair the prognosis of patients. Moreover, low expression of NEDD4L was prone to lymph node invasion, late stage and deprived prognosis (51, 52). These results suggest that NEDD4L might inhibit the progression of lung cancer. Further studies demonstrated that NEDD4L suppressed the proliferation,
migration and invasion of lung cancer cells (51). Enhancer of zeste homolog 2 (EZH2) is a highly conserved histone methyltransferase (HMTase) and is abnormally expressed in various cancers (53). Notably, EZH2 could weaken the expression of NEDD4L to serve as an oncogene in lung cancer (51). In addition, miR-93 is a member of the miR-106b-25 cluster and a driving force for the development of numerous cancers, such as bladder cancer, prostate cancer and lung cancer (54–56). MiR-93 mediated the decrease in NEDD4L expression and then enhanced TGF-β signaling to activate epithelial-to-mesenchymal transition (EMT) in lung cancer (57). Tumor-associated macrophages (TAMs) play a pivotal role in tumor aggressiveness and M2 macrophage-derived exosomes (MDEs) are critical communication media in the tumor microenvironment (50). MDE was reported to reduce the expression of NEDD4L and then stabilize the c-Myc protein to induce chemoresistance in lung cancer by transferring miR-3679-5p to cancer cells (58). In addition, NEDD4L be involved in the ubiquitination of multidrug resistance-associated protein 1 (MRP1), which was negatively correlated with the prognosis of cancer cells to a certain extent. 

**Endometrial Cancer**

Endometrial cancer is the sixth most common cancer in women, and the incidence and mortality of this cancer have increased in recent years (59). Endometrial cancer tissues showed decreased expression of NEDD4L compared with endometrial hyperplasia tissues utilizing immunohistochemical staining (66). However, there is a lack of research investigating the relationship between the level of NEDD4L and the initiation, development and outcomes of endometrial cancer.

**Prostate Cancer**

The expression and functions of NEDD4L in prostate cancer are still ambiguous. The expression of NEDD4L was decreased in prostate cancer specimens compared with benign prostatic hyperplasia (67). Interestingly, the expression of three NEDD4L transcripts, NEDD4Ld, NEDD4Lg and NEDD4Lh, was upregulated in prostate cancer cells after androgen administration (68, 69). NEDD4L was also downregulated in androgen-independent prostate cancer cells (70). It was suggested that the dysregulation of NEDD4L might result from the level of androgen. Additionally, SOX5 and DNA methylation possibly acted as regulators of NEDD4L in androgen-independent cancer cells (70). However, the study failed to show the molecular mechanisms by which NEDD4L modulated prostate carcinogenesis. Unexpectedly, Hellwinkel et al. reported that the level of NEDD4L was higher in prostate cancer tissues than in adjacent normal tissues (71). Furthermore, NEDD4L might contribute to the development of prostate cancer by reducing the TGF-β signaling pathway (71). Hence, the function of NEDD4L in prostate cancer is not clear.

**Renal Cancer**

Renal cell carcinoma (RCC) is a common malignant tumor in the urinary system (37). It was reported that the expression of NEDD4L was positively related to overall survival and disease-specific survival (DSS) in clear cell renal cell carcinoma (ccRCC) and chromophobe cell renal carcinoma (CCRC) (72, 73). In further studies, NEDD4L could limit the proliferation and metastasis of ccRCC cells by weakening the ERBB3 and MAPK signaling pathways (73). Consequently, NEDD4L can be considered as a potential therapeutic target in ccRCC.

**Breast Cancer**

Breast cancer is the most common malignancy in females, and hormones, reproduction and lifestyle may affect the
tumorigenesis of breast cancer (74). It was reported that a high level of NEDD4L might indicate a beneficial prognosis with free recurrence (75). In various breast cancer cells, miR-106b-25 could inhibit the expression of NEDD4L to upregulate the level of NOTCH1, which was instrumental in tumor-initiating cell (TIC) induction (75, 76). In addition, pseudokinase Tribble 3 (TRIB3) interacted with Akt and repressed NEDD4L-mediated ubiquitination of Forkhead box O1 (FOXO1) and then promoted the expression of Sry-related high-mobility box 2 (SOX2), a transcription factor of cancer stem cells, to exacerbate the development of breast cancer stem cells (77). NEDD4L modulated the degradation of copper transporter 1 (CTR1) in ubiquitination and exerted tumor inhibition through the CTR1-Akt signaling pathway (78). Several studies found that NEDD4L was probably implicated in the anticancer or cancer-promoting effects of some substances in breast cancer. For instance, selenium (Se) is a lurking anticancer nutrient (79), and NEDD4L is considered as a key gene in the regulatory network of the Se-stimulated epigenome (80). Unexpectedly, Orai3 advanced calcium influx, activated NEDD4L and reduced the apoptosis of breast cancer cells by weakening the expression of p53 (81). The relationship between NEDD4L and p53 has been reported, and NEDD4L might promote the survival of cancer cells (82). In brief, most research suggests that NEDD4L suppresses the malignant biological behavior of breast cancer cells, and further studies are necessary to discover its underlying mechanism in breast carcinogenesis.

**Other Human Cancers**

NEDD4L, activated by a functional polypeptide (JP1), induced degradation of SP1 via the ubiquitin-proteasome pathway and then attenuated the transcription of integrin αvβ3 to inhibit cell proliferation and metastasis of melanoma (83). In addition, serum- and glucocorticoid-regulated kinase 1 (SGK1) inhibited the degradation of the transcription factor JunB by NEDD4L in most cancer cells (84). The number of lung tumors in SGK1-deficient mice was much less than that in control mice after injection of melanoma cells into the tail vein (84). This finding indicated that NEDD4L might exert antitumor effects in melanoma. However, a study found that the expression of NEDD4L in cutaneous melanoma and lymph node metastatic melanoma was higher than that in normal melanocytes or benign nevus tissue (85). Overexpression of NEDD4L promoted the growth of A2058 melanoma cells in vivo, and downregulation of NEDD4L reduced the growth of G361 melanoma cells in vitro (85). Therefore, the role of NEDD4L in the development of melanoma is controversial and needs to be further clarified.

The expression of NEDD4L was in negatively correlated with the pathological grade of malignant glioma, and low expression of NEDD4L indicated poor outcomes (86). In addition, NEDD4L was reported as a direct target of miR-513a-5p, delayed the growth of glioma cells and amplified the cytotoxicity of temozolomide (TMZ) (87). Moreover, NEDD4L mediates the ubiquitination of the tumor oncogene sphingosine kinase 2 (SpHK2) and thus suppresses the development of malignant glioma (88). Consequently, NEDD4L mainly crippled the malignant biological behavior of glioma. The role of NEDD4L in lymphoma has also been investigated. A study demonstrated that the expression of NEDD4L in Sezary syndrome (SS) was much higher than that in healthy controls (89). It was reported that NEDD4L might be involved in the progression of diffuse large B cell lymphoma (DLBCL) (90). Nevertheless, the specific effect of NEDD4L on lymphoma has not been confirmed. NEDD4L was found to be downregulated and correlated with biosynthesis and metabolism in clear-cell renal cell cancer (ccRCC) by integrated bioinformatics analysis. Low expression of NEDD4L was associated with dismal prognosis in ccRCC, suggesting that NEDD4L could act as a prognostic biomarker and therapeutic target in ccRCC (72). A bioinformatics analysis revealed that NEDD4L was downregulated in esophageal cancer patients and might be associated with esophageal cancer prognosis (91).

**TARGETING NEDD4L FOR CANCER THERAPY**

Emerging evidence has demonstrated that several compounds can target the expression of NEDD4L. For example, β,β-dimethyl-acryl-alkannin (ALCAP2), a natural small-molecule compound separated from the root of Lithospermum erythrorhizon, could increase the expression of NEDD4L to hinder the nuclear translocation of β-catenin and stimulate the conjunction of ubiquitin and β-catenin, thus blocking the Wnt signaling pathway and inhibiting cell proliferation and metastasis as well as inducing apoptosis and cell cycle arrest in LUAD (92). Dexamethasone, a pretreatment drug, has been used for cancer treatment to reduce the toxic effect of chemotherapy. Dexamethasone was reported to promote the lung metastasis of breast cancer by regulating the PI3K-SGK1-CTGF pathway through the NEDD4L-Smad2 axis (93). AG490, an inhibitor of the Janus tyrosine kinase 2 (JAK2), can promote human organic anion transporter-3 (hOAT3) ubiquitination and degradation by enhancing the binding of NEDD4L with hOAT3 and reducing NEDD4L phosphorylation (94). Wogonin, a natural flavonoid agent, was revealed to upregulate the expression of NEDD4L and suppress the PI3K/Akt pathway (95). Therefore, targeting NEDD4L with these compounds might be helpful for cancer therapy in the future.

**CONCLUSIONS**

In conclusion, NEDD4L suppresses the carcinogenesis by elevating the degradation of substrates of NEDD4L in most cancer types, while the role of NEDD4L in a few cancer types still remains controversial (Figure 2 and Table 1). Modulating upstream genes can affect the expression of NEDD4L and thus influence the progression of cancers (Figure 2 and Table 2). It is important to mention that NEDD4L has mutations, copy number variations (CNV) gains, and CNV losses in a variety of human cancers (Figure 3). In some specific malignant tumors,
FIGURE 2 | Upstream and downstream genes of NEDD4L are illustrated.

TABLE 1 | NEDD4L gene modulates downstream genes and its impact on cancers.

| Cancer            | Downstream gene | Function                                                                 | Reference |
|-------------------|-----------------|---------------------------------------------------------------------------|-----------|
| Colorectal cancer | STK35           | accelerates glycolysis, decreases apoptosis, attenuates chemosensitivity  | (42)      |
| Melanoma          | STK35           | enhances TH2 differentiation                                              | (84)      |
| Pancreatic cancer | LTF             | binds to iron and transports iron                                          | (47)      |
|                   | ULK1            | involves in initiating cell autophagy                                     | (30)      |
| Lung cancer       | MRP1            | relates to multidrug resistance                                            | (59)      |
|                   | GCN2            | increases the cell apoptosis                                               | (60)      |
| Breast cancer     | NOTCH1          | takes part in TIC induction                                                | (75)      |
| Ovarian cancer    | TGF-β           | inhibits the cell proliferation                                            | (28)      |
|                   | FOXO1           | promotes breast cancer stemness                                            | (77)      |
|                   | CTR1            | is the predominant transporter of copper and elevates the development of cancer | (78)      |
| Glioma            | SphK2           | increases the cell proliferation and EMT                                   | (88)      |

TABLE 2 | Upstream gene modulates NEDD4L gene and its impact on cancers.

| Cancer            | Upstream gene | Function                                                                 | Reference |
|-------------------|---------------|---------------------------------------------------------------------------|-----------|
| Pancreatic cancer | miR-23A       | promotes proliferation, migration and invasiveness                        | (45, 96)  |
|                   | NDRG1         | suppresses iron-regulated metastasis                                      | (46)      |
| Lung cancer       | EZH2          | regulates cell cycle, apoptosis and metastasis                            | (51)      |
|                   | miR-93        | enhances TGF-β-induced EMT                                                | (57)      |
|                   | miR-3679-5p   | stabilizes the c-Myc protein to induce chemoresistance                    | (58)      |
| Ovarian cancer    | DDBP2         | participates in gene transcription and cell cycle regulation              | (65)      |
| Breast cancer     | miR-106b-25   | takes part in TIC induction                                               | (73)      |
|                   | TRIB3         | possesses tumor initiation capacity                                        | (77)      |
| Glioma            | miR-513a-5p   | influences the growth of glioma cells and reduces the cytotoxicity of TMZ  | (67)      |
the design of the NEDD4L enhancer may contribute to the better treatment of cancer patients, but the targeted inhibition of NEDD4L probably controls the procedure of some other cancer types. Additionally, the concrete mechanisms have not been fully elucidated, although there are abundant studies proving that NEDD4L plays oncogenic or tumor-suppressive roles in cancers by modulating its substrates. More detailed mechanistic research should be carried out to fully understand the function and role of NEDD4L in tumorigenesis. It is also critical to design and develop NEDD4L enhancers and inhibitors for cancer treatment in patients with dysregulation of NEDD4L. We believe that the clinical application of NEDD4L enhancers or inhibitors in cancer therapy will be prospective in the near future.

AUTHOR CONTRIBUTIONS

SX and XZ wrote this manuscript. LX and HL searched the literature regarding NEDD4L and cancers. YS and SX prepared the figures and tables. Z-wW was critically involved in discussion. All authors contributed to the article and approved the submitted version.
REFERENCES

1. Rieser E, Cordier SM, Walczak H. Linear Ubiquitination: A Newly Discovered Regulator of Cell Signalling. Trends Biochem Sci (2013) 38(2):94–102. doi: 10.1016/j.tibs.2012.11.007

2. Sun T, Liu Z, Yang Q. The Role of Ubiquitination and Deubiquitination in Cancer Metabolism. Mol Cancer (2020) 19(1):146. doi: 10.1186/s12934-020-01262-x

3. Hershko A, Ciechanover A. The Ubiquitin System. Annu Rev Biochem (1998) 67:425–79. doi: 10.1146/annurev.biochem.67.1.425

4. Mansour MA. Ubiquitination: Friend and Foe in Cancer. Int J Biochem Cell Biol (2018) 101:80–93. doi: 10.1016/j.biocel.2018.06.001

5. Weissman AM, Shabek N, Ciechanover A. The Predator Becomes the Prey: Regulating the Ubiquitin System by Ubiquitination and Degradation. Nat Rev Mol Cell Biol (2011) 12(9):603–20. doi: 10.1038/nrm3173

6. Buxto L, Huang DT. Structural Insights Into the Catalysis and Regulation of E3 Ubiquitin Ligases. Nat Rev Mol Cell Biol (2016) 17(10):626–42. doi: 10.1038/nrm3691

7. Qian H, Zhang Y, Wu B, Wu S, You S, Zhang N, et al. Structure and Function of HECT E3 Ubiquitin Ligases and Their Role in Oxidative Stress. J Transl Med (2020) 8(2):71–9. doi: 10.2478/jtm-2020-0012

8. Ciechanover A. The Ubiquitin-Proteasome Proteolytic Pathway. Cell (1994) 79(1):13–21. doi: 10.1002/0092-8674(94)90356-4

9. Wang ZW, Xu Y, Xie M, Lin M, Chu M, Shen X. NEDD4 E3 Ligase: Functions and Mechanism in Human Cancer. Semin Cancer Biol (2020) 67(7Pt 1):2020.03.006

10. Ye X, Wang L, Shang B, Wang Z, Wei W. NEDD4: A Promising Target for Cancer Therapy. Curr Cancer Drug Targets (2014) 14(6):549–56. doi: 10.2174/156809166667125092430

11. Goel P, Manning JA, Kumar S. NEDD4-2 (NEDD4L): The Ubiquitin Ligase for Multiple Membrane Proteins. Gene (2015) 557(1):1–10. doi: 10.1016/j.gene.2014.11.051

12. Ishigami T, Kino T, Minegishi S, Araki N, Umemura M, Ushio H, et al. Regulators of Epithelial Sodium Channels in Aldosterone-Sensitive Distal Nephrons (ASDN): Critical Roles of Nedd4L/Nedd4-2 and Salt-Sensitive Hypertension. Int J Mol Sci (2020) 21(11):3871. doi: 10.3390/jms21113871

13. Zhao F, Gong X, Liu A, Lv X, Hu B, Zhang H. Downregulation of Nedd4L Predicts Poor Prognosis, Promotes Tumor Growth and Inhibits MAPK/ERK Signal Pathway in Hepatocellular Carcinoma. Biochem Biophys Res Commun (2018) 495(1):1136–43. doi: 10.1016/j.bbrc.2017.11.139

14. Takeuchi T, Adachi Y, Nagayama T, Furuhata M. NEDD4L Modulates the Transcription of Metalloproteinase-1 and -13 Genes to Increase the Invasive Activity of Gallbladder Cancer. Int J Exp Pathol (2011) 92(2):79–86. doi: 10.1111/j.1365-2610.2010.00740.x

15. Yang B, Kumar S. Nedd4 and Nedd4-2: Closely Related Ubiquitin-Protein Ligases With Distinct Physiological Functions. Cell Death Differ (2010) 17(1):67–78. doi: 10.1038/cdd.2009.84

16. Corbalan-Garcia S, Gomez-Fernandez JC. Signaling Through C2 Domains: More Than One Lipid Target. Biochim Biophys Acta (2014) 1836(6):1536–47. doi: 10.1016/j.bbamem.2014.01.008

17. Mari S, Ruetalo N, Maspero E, Stoffregen MC, Passalaqua S, Polo S, et al. Structural and Functional Framework for the Autoinhibition of NEDD4-Family Ubiquitin Ligases. Structure (2014) 22(11):1639–49. doi: 10.1016/j.str.2014.09.006

18. Todoraro DR, Augustus-Wallace AC, Klein JM, Haas AL. The Mechanism of Neuro Precursor Cell Expressed Developmentally Down-Regulated 4 (Nedd4-2)/Nedd4L-Catalyzed Polyubiquitin Chain Assembly. J Biol Chem (2017) 292(47):19521–36. doi: 10.1074/jbc.M117.817782

19. Zhu K, Shan Z, Chen X, Cai Y, Cui L, Yao W, et al. Allosteric Auto-Inhibition and Activation of the Nedd4 Family E3 Ligase Itch. EMBO Rep (2017) 18(9):1568–30. doi: 10.15252/embr.201744454

20. Plant PJ, Yeager H, Staub O, Howard P, Rotin D. The C2 Domain of the Ubiquitin Protein Ligase Nedd4 Mediates Ca2+–Dependent Plasma Membrane Localization. J Biol Chem (1997) 272(51):32329–36. doi: 10.1074/jbc.272.51.32329

21. Ding Y, Zhang Y, Xu C, Tao QH, Chen YG. HECT Domain-Containing E3 Ubiquitin Ligase NEDD4L Negatively Regulates Wnt Signaling by Targeting Dvl/Day to Suppress Professional Degradation. J Biol Chem (2013) 288(12):8289–98. doi: 10.1074/jbc.M112.333385

22. Manning JA, Kumar S. Physiological Functions of Nedd4-2: Lessons From Knockout Mouse Models. Trends Biochem Sci (2018) 43(8):635–47. doi: 10.1016/j.tibs.2018.06.004

23. Kamynina E, Debonneville C, Bens M, Vandewalle A, Staub O. A Novel Mouse Nedd4 Protein Suppresses the Activity of the Epithelial Na+ Channel. FASEB J (2001) 15(1):204–14. doi: 10.1096/fj.99-01916cm

24. Hughes JR, Parsons JL. The E3 Ubiquitin Ligase NEDD4 Targets OGG1 for Ubiquitylation and Modulates the Cellular DNA Damage Response. Front Cell Dev Biol (2020) 8:607060. doi: 10.3389/fcel.2020.607060

25. Zhao R, Cui T, Han C, Zhang X, He J, Srivastava AK, et al. Downregulation of NEDD4 and Nedd4-2 Using Proteome Arrays. Mol Syst Biol (2009) 5:333. doi: 10.1038/msb.2009.85

26. Zhao R, Cui T, Han C, Zhang X, He J, Srivastava AK, et al. DDB2 Modulates TGF-β1 Signal Transduction in Human Ovarian Cancer Cells by Downregulating NEDD4L. Nucleic Acids Res (2015) 43(16):7838–49. doi: 10.1093/nar/gkv667

27. Nazio F, Cecconi F. Anticytotoxicity Of Tumour Cells In Mice With Anticancer Activity. J Natl Cancer Inst (1994) 86:197–203. doi: 10.1093/jnci/86.3.197

28. Gao P, Ma X, Yuan M, Yi Y, Liu G, Wen M, et al. E3 Ligase Nedd4l Promotes Antiviral Innate Immunity by Catalyzing K29-Linked Cysteine Ubiquitination of TRAF3. Nat Commun (2021) 12(1):1194. doi: 10.1038/s41467-021-21456-1

29. Kapoor S, Takeuchi T, Goto N, Kito Y, Furuhata M. Role of Altered Expression of Nedd4L in the Pathogenesis of Systemic Malignancies. Int J Exp Pathol (2012) 93(6):463–4. doi: 10.1111/j.1365-2612.2012.08343.x

30. Persaud A, Alberts P, Amsen EM, Xiong X, Wasmuth J, Saadon Z, et al. Comparison of Substrate Specificity of the Ubiquitin Ligases Nedd4 and Nedd4-2 Using Proteome Arrays. Mol Syst Biol (2009) 5:333. doi: 10.1038/msb.2009.85

31. Zhao R, Cui T, Han C, Zhang X, He J, Srivastava AK, et al. NEDD4L Regulates Wnt Signalling and mTORC1 Activity of Gallbladder Cancer. Front Cell Dev Biol (2020) 8:582695. doi: 10.3389/fcell.2020.582695

32. Supiot S, Gouraud W, Campion L, Jezequel P, Buecher B, Charrier J, et al. Early Dynamic Transcriptomic Changes During Preoperative Radiotherapy in
Patients With Rectal Cancer: A Feasibility Study. World J Gastroenterol (2013) 19(21):3249–54. doi: 10.3748/wjg.v19.i21.3249
44. Frampton AE, Castellano L, Colombo T, Giovannetti E, Krell J, Jacob J, et al. Integrated Molecular Analysis to Investigate the Role of microRNAs in Pancreatic Tumour Growth and Progression. Lancet (2015) 385(Suppl 1): S37. doi: 10.1016/S0140-6736(15)60352-X
45. Frampton AE, Castellano L, Colombo T, Giovannetti E, Krell J, Jacob J, et al. MicroRNAs Cooperatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression. Gastroenterology (2014) 146(1):268–77 e18. doi: 10.1053/j.gastro.2013.10.010
46. Kovacevic Z, Chikhani S, Lui GT, Sivagurunathan S, Richardson DR. The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways. Antioxid Redox Signal (2013) 18(8):874–87. doi: 10.1089/ars.2011.4723
47. Wang Y, Liu Y, Liu J, Kang R, Tang D. NEDD4L-Mediated LTF Protein Degradation Limits Ferroptosis. Biochem Biophis Res Commun (2020) 531 (4):581–7. doi: 10.1016/j.bbrc.2020.07.032
48. Sharma A, Sharma KL, Gupta A, Yadav A, Kumar A. Gallbladder Cancer Epidemiology, Pathogenesis and Molecular Genetics: Recent Update. World J Gastroenterol (2017) 23(22):3978–97. doi: 10.3748/wjg.v23.i22.3978
49. Bade BC, Delta Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med (2020) 41(1):1–24. doi: 10.1016/j.ccm.2019.10.001
50. Wu J, Gao W, Tang Q, Yu Y, Wu W, et al. M2 Macrophage-Derived Exosomes Facilitate HCC Metastasis by Transferring alphaMbeta2 Integrin to Tumor Cells. Hepatology (2021) 73(4):1365–80. doi: 10.1002/hep.31432
51. Wang X, Duan J, Fu W, Yin Z, Sheng J, Lei Z, et al. Decreased Expression of NEDD4L Contributes to NSCLC Progression and Metastasis. Biochem Biophis Res Commun (2019) 513(2):398–404. doi: 10.1016/j.bbrc.2019.04.001
52. Sakashita H, Inoue H, Akamine S, Ishida T, Inase N, Shirao K, et al. Precancerous Lesions Induced by Sodium Selenite in Breast Cancer Cells. A Paradigm of the “Common Soil” Hypothesis. Semin Cell Biol (2021) 72:4–10. doi: 10.1016/j.semcemcr.2020.02.010
53. Guarnieri AL, Towers CG, Drasen DJ, Aliphanat MUJ, Andryszik Z, Hotz TJ, et al. The miR-106b-25 Cluster Mediates Breast Tumor Initiation Through Activation of NOTCH1 via Direct Repression of NEDD4L. Oncogene (2018) 37(28):3879–93. doi: 10.1038/s41388-018-0239-7
54. Pires BR, DEA IS, Souza LD, Rodrigues JA, Mencalha AL. Targeting Cellular Signaling Pathways in Breast Cancer Stem Cells and its Implication for Cancer Treatment. Anticancer Res (2016) 36(11):5861–91. doi: 10.21873/anticancer.11151
55. Yu JM, Sun W, Wang ZH, Liang H, Hua F, Li K, et al. TRIB3 Supports Breast Cancer Stemness by Suppressing FOXO1 Degradation and Enhancing SOX2 Transcription. Nat Commun (2019) 10(1):5720. doi: 10.1038/s41419-018-1740-8
56. Guo J, Cheng J, Zheng N, Zhang X, Dai X, Zhang L, et al. Copper Promoters Augmentation by Activating the PDK1-AKT Oncogenic Pathway in a Copper Transporter 1 Dependent Manner. Adv Sci (Weinheim) (2021) 8:e2004303. doi: 10.1002/advs.202004303
57. Sandvedsen M, Nilsson E, Borgquist S, Rosendahl AH, Manjer J. Prediagnostic Serum Selenium Levels in Relation to Breast Cancer Survival and Tumor Characteristics. Int J Cancer (2015) 137(9):2424–33. doi: 10.1002/ijc.29301
58. Hasna J, Hague F, Rodat-Despoix L, Geerts D, Leroy C, Tulase D, et al. Oralis Calcium Channel and Resistance to Chemotherapy in Breast Cancer Cells: The P33 Connection. Cell Death Differ (2018) 25(4):693–707. doi: 10.1038/s41418-017-0067-1
59. Mathieu NA, Levin RH, Spratt DE. Exploring the Roles of HERC2 and the NEDD4L HECT E3 Ubiquitin Ligase Subfamily in P53 Signaling and the DNA Damage Response. Front Oncol (2021) 11:659049. doi: 10.3389/fonc.2021.659049
83. Cui J, Shu C, Xu J, Chen D, Li J, Ding K, et al. JP1 Suppresses Proliferation and Metastasis of Melanoma Through MEK1/2 Mediated NEDD4L-SP1-Integrin Alphavbeta3 Signaling. *Theranostics* (2020) 10(18):8036–50. doi: 10.7150/thno.45843

84. Heikamp EB, Patel CH, Collins S, Waickman A, Oh MH, Sun IH, et al. The AGC Kinase SGK1 Regulates TH1 and TH2 Differentiation Downstream of the Mtorc2 Complex. *Nat Immunol* (2014) 15(5):457–64. doi: 10.1038/ni.2867

85. Kito Y, Bai J, Goto N, Okubo H, Adachi Y, Nagayama T, et al. Pathobiological Properties of the Ubiquitin Ligase Nedd4L in Melanoma. *Int J Exp Pathol* (2014) 95(1):24–8. doi: 10.1111/iep.12051

86. He S, Deng J, Li G, Wang B, Cao Y, Tu Y. Down-Regulation of Nedd4L is Associated With the Aggressive Progression and Worse Prognosis of Malignant Glioma. *Jpn J Clin Oncol* (2012) 42(3):196–201. doi: 10.1093/jjco/hyr195

87. Chen KC, Chen PH, Ho KH, Shih CM, Chou CM, Cheng CH, et al. IGF-1-Enhanced miR-513a-5p Signaling Desensitizes Glioma Cells to Temozolomide by Targeting the NEDD4L-Inhibited Wnt/beta-Catenin Pathway. *PloS One* (2019) 14(12):e0225913. doi: 10.1371/journal.pone.0225913

88. Wang H, Zhao B, Bian E, Zong G, He J, Wang Y, et al. Ubiquitination Destabilizes Protein Sphingosine Kinase 2 to Regulate Glioma Malignancy. *Front Cell Neurosci* (2021) 15:660354. doi: 10.3389/fncel.2021.660354

89. Booken N, Gratchev A, Utikal J, Weiss C, Yu X, Qadoumi M, et al. Sezary Syndrome is a Unique Cutaneous T-Cell Lymphoma as Identified by an Expanded Gene Signature Including Diagnostic Marker Molecules CD01 and DNM3. *Leukemia* (2008) 22(2):393–9. doi: 10.1038/sj.leu.2405044

90. Qu Q, Li Y, Fang X, Zhang L, Xue C, Ge X, et al. Differentially Expressed lncRNAs in CD5 Positive Relapsed & Refractory Diffuse Large B Cell Lymphoma and the Bioinformatic Analysis for Their Potential Clinical Use. *Biol Direct* (2019) 14(1):23. doi: 10.1186/s13062-019-0255-8

91. Zhang H, He Y, Gu H, Liu Z, Li B, Yang Y, et al. Construction of a Nine-MicroRNA-Based Signature to Predict the Overall Survival of Esophageal Cancer Patients. *Front Genet* (2021) 12:670405. doi: 10.3389/fgene.2021.670405

92. Zhang W, Zhang R, Zeng Y, Li Y, Chen Y, Zhou J, et al. ALCAP2 Inhibits Lung Adenocarcinoma Cell Proliferation, Migration and Invasion via the Ubiquitination of Beta-Catenin by Upregulating the E3 Ligase NEDD4L. *Cell Death Dis* (2021) 12(8):755. doi: 10.1038/s41419-021-04043-6

93. Zhang Y, Shi G, Zhang H, Xiong Q, Cheng F, Wang H, et al. Dexamethasone Enhances the Lung Metastasis of Breast Cancer via a PI3K-SGK1-CTGF Pathway. *Oncogene* (2021) 40(35):5367–78. doi: 10.1038/s41388-021-01944-w

94. Zhang J, Liu C, You G. AG490, a JAK2-Specific Inhibitor, Downregulates the Expression and Activity of Organic Anion Transporter-3. *J Pharmacol Sci* (2018) 136(3):142–8. doi: 10.1016/j.physj.2018.01.006

95. Qian W, Yu D, Zhang J, Hu Q, Tang C, Liu P, et al. Wogonin Attenuates Isoproterenol-Induced Myocardial Hypertrophy in Mice by Suppressing the PI3K/Akt Pathway. *Front Pharmacol* (2018) 9:896. doi: 10.3389/fphar.2018.00896

96. Wang W, Ning JZ, Tang ZG, He Y, Yao LC, Ye L, et al. MicroRNA-23a Acts as an Oncogene in Pancreatic Carcinoma by Targeting TFPI-2. *Exp Ther Med* (2020) 20(5):53. doi: 10.3892/etm.2020.9181

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Xie, Xia, Song, Liu, Wang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.